What you need to know ### BMJ Learning To obtain accredited continuous professional development points, subscribers to BMJ Learning can complete the full module at The module contains seven ...
Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections in children under two years old, resulting in significant morbidity and a heavy economic burden on healthcare ...
During the COVID pandemic, RSV showed a slightly odd pattern: like flu, it basically disappeared in the 2020–2021 season, ...
From today, February 3, pregnant women in Australia will be eligible for a free RSV vaccine under the National Immunisation Program. This vaccine is designed to protect young infants from severe ...
Flu cases have been particularly prevalent in the Wood River Valley this winter, according to St. Luke’s Wood River data.
New kits are designed to offer a convenient method to label any antibody with one of Bio-Rad’s StarBright Dyes.
Inhalon's RSV candidate is one of several potential therapies being developed based on the company's inhaled antibody technology for acute respiratory infections. The inhaled route of ...
AstraZeneca and Sanofi have secured approval in the EU for Beyfortus, the first single-dose drug to protect newborns and infants from respiratory syncytial virus (RSV) infections. The antibody ...
GSK and Pfizer’s full-year financial results show that the former is currently winning the battle for take-up of their rival respiratory syncytial virus (RSV) vaccines, although, there are signs ...